Section Arrow
Quote
GLUE.NASDAQ
- Monte Rosa Therapeutics
Quotes are at least 15-min delayed:2026/07/15 15:15 EDT
Regular Hours
Last
 23.38
-0.08 (-0.34%)
Day High 
23.755 
Prev. Close
23.46 
1-M High
25.22 
Volume 
551.06K 
Bid
23.36
Ask
23.41
Day Low
22.562 
Open
23.18 
1-M Low
17.38 
Market Cap 
1.98B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 23.71 
20-SMA 21.89 
50-SMA 19.88 
52-W High 25.77 
52-W Low 4.12 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.48/-1.28
Enterprise Value
2.02B
Balance Sheet
Book Value Per Share
6.18
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
123.67M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VIVSVivoSim Lab Inc0.87385+0.03905+4.68%0.47PE
LIMNLiminatus Pharma Inc0.12165+0.01815+17.54%-- 
IOVAIovance Biotherapeutics4.66+0.73+18.58%-- 
ERNAErnexa Therapeutics Inc.6.5199+0.4599+7.59%0.01PE
GOSSGossamer Bio0.1561+0.016+11.42%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programsin clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.